• Children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season 
• Children with severe immunocompromise 
• Children with cystic fibrosis who have either 1) manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable), or 2) weight-for-length <10th percentile 
• American Indian or Alaska Native children 

Dosing: 

For infants less than 8 months of age in their first RSV season, one dose of nirsevimab should be administered, based on weight: 

• 50 mg for infants weighing <5 kg [<11 lb]  
• 100 mg for infants weighing ≥5 kg [≥11 lb]  

For infants and children aged 8–19 months who are at increased risk for severe RSV disease (as noted below) and entering their second RSV season: 

• 200 mg, administered as two 100 mg injections given at the same time at different injection sites 

Ordering: 

Nirsevimab is now available to order through the VFC program and can be ordered through the WIR ordering screen. 

Additional information: 

It is important to note that per CDC, the provider agreement is being updated to address specific considerations related to nirsevimab. Updates include: 

• Definition of “vaccine” as it is used by the VFC program: For the purposes of the VFC program, the term ‘vaccine’ is defined as any FDA-authorized or licensed, ACIP-recommended product for which ACIP approves a VFC resolution for inclusion in the VFC program. 
• Requirement to provide patients with an Immunization Information Statement, as opposed to a Vaccine Information Statement (VIS), prior to administration of nirsevimab. 
• Requirement to report adverse events following administration of nirsevimab to MedWatch, unless co-administered with a vaccine. 

Note that by ordering nirsevimab, providers are agreeing to these stipulations and no signature/updated agreement is needed at this time. These will be included in the next year’s re-enrollment.